Skip to main content

Advertisement

SpringerLink
Log in

Assessment of hypercoagulability markers and lipid levels in postmenopausal women undergoing either oral or transdermal hormone replacement therapy

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Background This study investigated the effect of either oral or transdermal hormone replacement therapy (HRT) on haemostatic, fibrinolytic and lipid profiles in a group of Brazilian women 3 months after beginning treatment by comparing these results with those obtained immediately before HRT. Methods Plasma levels of TAT, DDi, F1+2, PC, PS, AT, PAI-1 and serum lipids were determined in blood samples collected from 24 women undergoing oral HRT and from 11 women undergoing transdermal HRT. Results Significant increases in DDi and F1+2 plasma levels were observed after 3 months of oral HRT, while PS levels decreased. After transdermal HRT, a significant decrease was observed only for AT levels. Conclusion After 3 months of oral HRT and in the absence of major genetic and acquired risk factors, women displayed a predisposition for activation of blood coagulation, and an increased activity of the fibrinolytic system. Oral HRT seemed to be more effective in predisposing haemostatic changes as compared to transdermal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ettinger B (1988) Prevention of osteoporosis: treatment of estradiol deficiency. Obstet Gynecol 72:12S–17S

    PubMed  CAS  Google Scholar 

  2. Grady D, Rubin SM, Petitti DB et al (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117:1016–1037

    PubMed  CAS  Google Scholar 

  3. Stevenson JC (2000). Cardiovascular effects of oestrogens. J Steroid Biochem Mol Biol 74:387–403

    Article  PubMed  CAS  Google Scholar 

  4. Hulley S, Grady D, Bush T et al (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopaulsal women (HERS). JAMA 280:605–613

    Article  PubMed  CAS  Google Scholar 

  5. Women’ S Health Initiative—WHI (2002) Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333

    Article  Google Scholar 

  6. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S (1996) Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348:977–980

    Article  PubMed  CAS  Google Scholar 

  7. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Perez-Gutthann S (1998) Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 147:387–390

    PubMed  CAS  Google Scholar 

  8. Miller J, Chan BKS, Nelson HD (2002) Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. preventive services task force. Ann Intern Med 136:680–690

    PubMed  CAS  Google Scholar 

  9. Wu O, Robertson L, Langhorne P et al (2005) Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The thrombosis: risk and economic assessment of thrombophilia screening (TREATS) study. Thromb Haemost 94:17–25

    PubMed  CAS  Google Scholar 

  10. Hoibraaten E, Abdelnoor M, Sandset PM (1999) Hormone replacement therapy with estradiol and risk of venous thromboembolism: a population-based case-control study. Thromb Haemost 82:1218–1221

    PubMed  CAS  Google Scholar 

  11. Grady D, Wenger NK, Herrington D et al (2000) Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The heart and estrogen/progestin replacement study. Ann Intern Med 132:689–696

    PubMed  CAS  Google Scholar 

  12. Rosendaal FR, Vessey M, Rumley A et al (2002) Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 116:851–854

    Article  PubMed  CAS  Google Scholar 

  13. Herrington DM, Vittinghoff E, Howard TD et al (2002) Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 22:1012–1017

    Article  PubMed  CAS  Google Scholar 

  14. Douketis JD, Gordon M, Johnston M, Julian JA, Adachi JR, Ginsberg JS (2000) The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature. Thromb Res 99:25–34

    Article  PubMed  CAS  Google Scholar 

  15. Teede HJ, Mcgrath BP, Smolich JJ et al (2000) Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 20:1404–1409

    PubMed  CAS  Google Scholar 

  16. Salobir BG, Keber I, Vrabic L (2002) A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women. Fertil Steril 79:1178–1183

    Article  Google Scholar 

  17. Gottsäter A, Rendell M, Hulthén UL, Berntorp E, Mattiasson I (2001) Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Intern Med 249:237–246

    Article  PubMed  Google Scholar 

  18. Lowe GDO, Upton MN, Rumley A, McConnachie A, O’Reilly DSJ, Watt GCM (2001) Different effects of oral transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein: a cross-sectional population survey. Thromb Haemost 86:550–556

    PubMed  CAS  Google Scholar 

  19. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T et al (2001) Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 85:619–625

    PubMed  CAS  Google Scholar 

  20. Frosst P, Blom HJ, Milos R et al (1995) A candidate risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111–113

    Article  PubMed  CAS  Google Scholar 

  21. Huber S, McMaster KJ, Voelkerding KV (2000) Analytical evaluation of primer engineered multiplex polymerase chain reaction-restriction fragment length polymorphism for detection of Factor V Leiden and prothrombin G20210A. J Mol Diagn 2:153–157

    PubMed  CAS  Google Scholar 

  22. Stevenson JC (2000). Cardiovascular effects of estrogens. J Steroid Biochem Mol Biol 74:387–393

    Article  PubMed  CAS  Google Scholar 

  23. Caine YG, Bauer KA, Barzegar S et al (1992) Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 68:392–395

    PubMed  CAS  Google Scholar 

  24. Kroon UB, Silfverstolpe G, Tengborn L (1994) The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 71:420–503

    PubMed  CAS  Google Scholar 

  25. Borgfeldt C, Li C, Samsioe G (2004) Low-dose oral combination of 17beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1. Climacteric 7:78–85

    Article  PubMed  CAS  Google Scholar 

  26. Koh KK, Horne MK, Csako G, Waclawiw MA, Cannon III RO (1999) Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women. Am J Cardiol 83:466–469

    Article  PubMed  CAS  Google Scholar 

  27. Gilabert J, Estelles A, Cano A et al (1995) The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 173:1849–1854

    Article  PubMed  CAS  Google Scholar 

  28. Madsen JS, Kristensen SR, Gram J et al (2003) Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women. Thromb Haemost 1:1984–1991

    Article  CAS  Google Scholar 

  29. Psaty BM, Smith NSL, Lemaitre RN et al (2001) Hormone replacement therapy, protrombotic mutations, and risk of incidence non-fatal myocardial infarction. JAMA 285:906–913

    Article  PubMed  CAS  Google Scholar 

  30. Guimaraes DA, Cardoso J, Dusse LM et al (2006) Effect of oral hormone replacement therapy on plasma homocysteine levels. Acta Obstet Gynecol Scand 85:1304–1306

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work received financial support from the CNPq, CAPES and FAPEMIG and from the Program “Redes Cooperativas de Pesquisa de Minas Gerais” (RECOPE-MG-REC-32-082/99).

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, Federal University of Minas Gerais, Av. Antonio Carlos, 6627, Belo Horizonte, Minas Gerais, CEP: 31270-901, Brazil

    Daniela Amorim Melgaço Guimarães, Maria das Graças Carvalho, Jarbas Cardoso, Marinez de Oliveira Sousa, Luci Maria Sant´Ana Dusse & Ana Paula Fernandes

  2. Maternidade Otaviano Neves, Belo Horizonte, Minas Gerais, Brazil

    Romerson Martins Franco, Hilton de Almeida Franco, Túlio César Alvim & George da Silva Teixeira

Authors
  1. Daniela Amorim Melgaço Guimarães
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria das Graças Carvalho
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jarbas Cardoso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marinez de Oliveira Sousa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Romerson Martins Franco
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hilton de Almeida Franco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Túlio César Alvim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. George da Silva Teixeira
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Luci Maria Sant´Ana Dusse
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ana Paula Fernandes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniela Amorim Melgaço Guimarães.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guimarães, D.A.M., das Graças Carvalho, M., Cardoso, J. et al. Assessment of hypercoagulability markers and lipid levels in postmenopausal women undergoing either oral or transdermal hormone replacement therapy. J Thromb Thrombolysis 27, 135–140 (2009). https://doi.org/10.1007/s11239-007-0169-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-007-0169-7

Keywords

Search

Navigation